Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Anticancer Research|May 13, 2015
Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel ResponseTakuya Ohashi, Tatsuya Yoshimasu, Shoji Oura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 30, 2004
[Histoculture drug response assay guided concurrent chemoradiotherapy for lung metastasis from adrenocortical carcinoma--a case report]Tatsuya Yoshimasu, Shoji Oura, Issei Hirai, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 30, 2007
Data acquisition for the histoculture drug response assay in lung cancerTatsuya Yoshimasu, Shoji Oura, Issei Hirai, et al.
Anticancer Research|October 28, 2015
A Theoretical Model for the Hormetic Dose-response Curve for Anticancer AgentsTatsuya Yoshimasu, Takuya Ohashi, Shoji Oura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 2, 2004
[Anastrozole-resistant breast cancer responsive to exemestane--a case report]Teruhisa Sakurai, Shoji Oura, Issei Hirai, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 22, 2009
[Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer]Yoshimitsu Hirai, Tatsuya Yoshimasu, Shoji Oura, et al.
Breast Cancer Research and Treatment|February 10, 2017
Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancerHiroji Iwata, Norikazu Masuda, Daigo Yamamoto, et al.
Breast Cancer (Tokyo, Japan)|November 8, 2007
In vitro evaluation of dose-response curve for paclitaxel in breast cancerTatsuya Yoshimasu, Shoji Oura, Issei Hirai, et al.
Pageof 14